Eric A Klein1, Ian M Thompson. 1. Glickman Urological and Kidney Institute, Desk Q10-1, 9500 Euclid Ave, Cleveland, OH 44122, USA. kleine@ccf.org
Abstract
OBJECTIVES: To place chemoprevention of prostate cancer in current clinical context. METHODS: Review of recently published updates of large, randomized, controlled trials of primary chemoprevention of prostate cancer. RESULTS: With extended post-intervention follow-up, SELECT demonstrated a 17% increased risk of prostate cancer relative to placebo in the vitamin E alone arm. Two other trials in men with high-grade PIN demonstrated no effect of selenium alone or in combination with soy and lycopene. Trials of 5α-reductase inhibitors show an approximate 25% relative risk reduction in men at average risk and in those with an "elevated" PSA and prior negative biopsy, but adoption of these agents in clinical practice has been limited by concerns over an apparently increased risk of high-grade disease. CONCLUSIONS: Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity. Neither selenium nor vitamin E prevents prostate cancer. The benefit/risk ratio for 5α-reductase inhibitors can be improved by limiting their use to men at high risk.
OBJECTIVES: To place chemoprevention of prostate cancer in current clinical context. METHODS: Review of recently published updates of large, randomized, controlled trials of primary chemoprevention of prostate cancer. RESULTS: With extended post-intervention follow-up, SELECT demonstrated a 17% increased risk of prostate cancer relative to placebo in the vitamin E alone arm. Two other trials in men with high-grade PIN demonstrated no effect of selenium alone or in combination with soy and lycopene. Trials of 5α-reductase inhibitors show an approximate 25% relative risk reduction in men at average risk and in those with an "elevated" PSA and prior negative biopsy, but adoption of these agents in clinical practice has been limited by concerns over an apparently increased risk of high-grade disease. CONCLUSIONS: Primary prevention of prostate cancer remains an attractive goal because of its prevalence and treatment-related morbidity. Neither selenium nor vitamin E prevents prostate cancer. The benefit/risk ratio for 5α-reductase inhibitors can be improved by limiting their use to men at high risk.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson Journal: J Urol Date: 2011-01-15 Impact factor: 7.450
Authors: Michael Marberger; Stephen J Freedland; Gerald L Andriole; Mark Emberton; Curtis Pettaway; Francesco Montorsi; Claudio Teloken; Roger S Rittmaster; Matthew C Somerville; Ramiro Castro Journal: BJU Int Date: 2011-06-23 Impact factor: 5.588
Authors: Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano Journal: JAMA Date: 2008-11-09 Impact factor: 56.272
Authors: David R McCance; Valerie A Holmes; Michael J A Maresh; Christopher C Patterson; James D Walker; Donald W M Pearson; Ian S Young Journal: Lancet Date: 2010-06-26 Impact factor: 79.321
Authors: Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg Journal: JAMA Date: 2007-06-06 Impact factor: 56.272
Authors: J Michael Gaziano; Robert J Glynn; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Howard D Sesso; Julie E Buring Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: David M Latini; Stacey L Hart; Sara J Knight; Janet E Cowan; Phillip L Ross; Janeen Duchane; Peter R Carroll Journal: J Urol Date: 2007-07-16 Impact factor: 7.450
Authors: Daimantas Milonas; Stasys Auskalnis; Giedrius Skulcius; Inga Gudinaviciene; Mindaugas Jievaltas; Steven Joniau Journal: World J Urol Date: 2016-09-19 Impact factor: 4.226
Authors: Stacey A Kenfield; Julie L Batista; Jaquelyn L Jahn; Mary Kathryn Downer; Erin L Van Blarigan; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; June M Chan Journal: J Natl Cancer Inst Date: 2015-11-17 Impact factor: 13.506
Authors: Andrei Moroz; Flávia K Delella; Rodrigo Almeida; Lívia Maria Lacorte; Wágner José Fávaro; Elenice Deffune; Sérgio L Felisbino Journal: PLoS One Date: 2013-12-30 Impact factor: 3.240
Authors: Tomasz Golabek; Jakub Bukowczan; Robert Sobczynski; Jaroslaw Leszczyszyn; Piotr L Chlosta Journal: Arch Med Sci Date: 2016-04-12 Impact factor: 3.318
Authors: Chandra K Singh; Mary A Ndiaye; Imtiaz A Siddiqui; Minakshi Nihal; Thomas Havighurst; KyungMann Kim; Weixiong Zhong; Hasan Mukhtar; Nihal Ahmad Journal: Oncotarget Date: 2014-06-15